G rowth-differentiation factor-15 (GDF-15) is a distant member of the transforming growth factor-␤ cytokine superfamily. Although GDF-15 is weakly expressed in most tissues under physiological conditions, 1,2 its expression levels may significantly increase in response to pathological stress associated with inflammation or tissue injury. 3, 4 Along that line, reactive oxygen species, proinflammatory cytokines, simulated ischemia, and mechanical stretch have been found to stimulate the expression of GDF-15 in cultured rat cardiomyocytes. 4 -6 Increased cardiac expression levels of GDF-15 have been observed in mouse models of myocardial infarction (MI), pressure overload, and cardiomyopathy, 4, 7, 8 indicating that GDF-15 shares some of its upstream regulatory stimuli with B-type natriuretic peptide (BNP). 9 In contrast to BNP, which is predominantly produced in the heart, 10 GDF-15 is not a cardiac-specific factor, however. Endothelial cells, for example, have been shown to express GDF-15 when exposed to antiangiogenic stress. 11, 12 Moreover, GDF-15 has been detected in human atherosclerotic plaque macrophages, where it may be induced by oxidized low-density lipoprotein (LDL) and proinflammatory cytokines. 1, 13 
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Data on the prospective impact of GDF-15 plasma concentrations in patients are evolving. A nested case-control analysis of the Women's Health Study found that the circulating level of GDF-15 is related to the risk of future cardiovascular (CV) events in elderly women with no previous evidence of CV disease. This effect was independent of traditional risk factors and C-reactive protein (CRP) levels. 14 Retrospective analyses of randomized clinical trials have shown that the circulating levels of GDF-15 are elevated in patients with acute coronary syndrome (ACS). [15] [16] [17] The levels of GDF-15 were strongly associated with the risk of all-cause mortality in these studies. Notably, the prognostic information provided by GDF-15 was independent of clinical variables and other risk markers, including renal dysfunction, CRP, cardiac troponin T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP), suggesting that GDF-15 provides insight into a distinct pathophysiological process. [15] [16] [17] Considering the relation of GDF-15 to stress signaling in different CV cell types, we hypothesized that GDF-15 may be associated with outcome across the broad spectrum of patients with stable and unstable coronary heart disease (CHD). To test this hypothesis, we measured the circulating level of GDF-15 and assessed its relation to clinical risk indicators, other biomarkers, and outcome in patients with angiographically proven CHD from the AtheroGene registry.
Methods

Patient Population and End Points
Between November 1996 and February 2004, patients with stable angina pectoris (SAP) or ACS who underwent coronary angiography at the Second Medical Department of the Johannes-Gutenberg University in Mainz or the German Federal Armed Forces Central Hospital in Koblenz, and who had at least 1 stenosis Ͼ30% in a major coronary artery were enrolled in the AtheroGene registry. Details of the study design have been published. 18, 19 Exclusion criteria included significant valvular heart disease or known cardiomyopathy, clinical or echocardiographic signs of heart failure, a history of coronary artery bypass graft surgery, percutaneous transluminal coronary angioplasty, pulmonary embolism, surgery, trauma, or use of oral anticoagulant therapy within the previous 4 weeks, febrile conditions or sepsis, and known cancer. Patients presenting after cardiopulmonary resuscitation were also excluded. For the current analyses, blood samples were available from 1352 patients with SAP and 877 patients with ACS (unstable angina according to Braunwald classes B and C, non-ST-elevation or ST-elevation MI). Patients who received antihypertensive treatment or who had blood pressure measurements Ͼ140/90 mm Hg were considered to have hypertension. Patients were classified as current smokers, previous smokers (if they had stopped Ͼ4 weeks and Ͻ40 years earlier), or never smokers (if they had never smoked or had stopped Ͼ40 years ago). Patients receiving dietary or drug treatment for diabetes or whose fasting blood glucose concentrations were Ͼ125 mg/dL were considered to have diabetes mellitus. Left ventricular ejection fraction (LVEF) was determined by angiography and off-line analysis by the area-length method in 757 SAP and 439 ACS patients. 18 Patients were followed for a median of 3.6 (maximum 6.9) years. All data were evaluated by an independent end point adjudication committee consisting of experienced physicians who were blinded to biomarker concentrations. CHD mortality (cardiac death, sudden cardiac death, fatal MI) and nonfatal MI were the end points of the present study. Information about the causes of death was obtained from hospital and general practitioner charts. Similarly, nonfatal MIs, as reported by the patients during follow-up, were validated using hospital and general practitioner charts and the ECG and biomarker criteria proposed by the European Society of Cardiology.
The study was approved by the ethics committee at the University of Mainz. Participation was voluntary, and each subject provided written, informed consent.
Laboratory Parameters and Biomarker Testing
Blood samples were drawn in all patients immediately before coronary angiography, rapidly processed, and stored at Ϫ80°C. Plasma concentrations of GDF-15 were determined by a recently developed and validated immunoradiometric assay with a linear range from 200 to 50000 ng/L. 20 Two GDF-15 cutoff points, 1200 and 1800 ng/L, were prospectively validated in the present study. The 1200 ng/L cutoff point corresponds to the previously defined upper reference limit in a cohort of 429 apparently healthy elderly individuals (median age, 65 years; 67.1% men). 20 A total of 1200 ng/L also correspond to the rounded lower tertile boundary in 2081 patients with non-ST-elevation ACS included in the Global Utilization of Strategies To Open occluded arteries (GUSTO) IV trial, whereas 1800 ng/L corresponds to the rounded upper tertile boundary in that patient population. These cutoff points were found to be useful for identifying patient subgroups at low risk (Ͻ1200 ng/L), intermediate risk (1200 to 1800 ng/L), or high risk (Ͼ1800 ng/L) of death in GUSTO IV and in another large non-ST-elevation ACS trial population. 15, 16 Data are reported as percentage, meanϮSD, or median (interquartile range). In the stable angina cohort, CRP values were available from 1262 patients, cTnI from 1119, NT-proBNP from 1290, and LVEF from 757; in the ACS cohort, CRP was available from 834 patients, cTnI from 771, NT-proBNP from 853, and LVEF from 439. LDL indicates low-density lipoprotein; HDL, high-density lipoprotein; ACE-I, ACE-inhibitor; and AT 1 -RA, AT 1 receptor antagonist.
NT-proBNP was measured by a sandwich immunoassay (Roche Diagnostics), high-sensitivity CRP by a latex particle-enhanced immunoassay (Roche Diagnostics), and cardiac troponin I (cTnI) by the current version of the AccuTnI assay (Beckman Coulter). Based on previous investigations that showed that a cTnI level Ͼ0.01 g/L was associated with CV high-risk features in elderly individuals 21 and was prognostically useful in patients with stabilized CHD, 22 this cutoff was used in the present analysis. Serum lipids and creatinine were measured by standard laboratory techniques. Estimated glomerular filtration rate (eGFR) was calculated according to the Cockcroft and Gault equation, and LDL cholesterol according to the Friedewald formula.
Statistical Methods
Baseline characteristics are shown as percentages or meanϮSD. Skewed variables are presented as median with interquartile range. The Kolmogorov-Smirnov test was used to test for a normal distribution of continuous variables. Multiple linear regression analysis was applied to identify factors that were independently associated with GDF-15. The Kaplan-Meier method was used to illustrate the timing of events during follow-up; statistical assessment was performed by the log-rank test. The relations of GDF-15 to outcome were assessed by backward stepwise Cox regression analyses, first adjusting for age and gender (model 1), and then adjusting also for classical risk factors (hypertension, smoking [never, previous, current], diabetes [no or dietary treatment, medical treatment, insulin treatment], LDL/HDL ratio), number of diseased vessels (left main stenosis was classified as 2-vessel disease), history of MI, eGFR, CRP, cTnI (Յ0.01 versus Ͼ0.01 g/L), and NT-proBNP (model 2); variables were entered one at a time; variables with a significant partial regression coefficient of PϽ0.10 were added to the model, and those with PϽ0.10 in the stepwise procedure were retained. The prognostic performance of the 2 prespecified GDF-15 cutoff values was assessed in the same age-adjusted, gender-adjusted and fully adjusted Cox regression models. Variables that were not normally distributed (eGFR, CRP, NT-proBNP, and GDF-15) were transformed to their natural logarithm for all regression analyses. To compare the prognostic information provided by a clinical risk model, which included information about age, gender, hypertension, diabetes (categorical), smoking (categorical), LDL/HDL ratio, number of diseased vessels, history of MI, and eGFR, alone and in combination with GDF-15, receiver operating characteristic curves were generated, and the area under the receiver operator characteristic curves were calculated and compared. 23 Probability values Ͻ0.05 were considered to indicate statistical significance. All analyses were performed using SPSS version 15.0.1 (SPSS Inc, Chicago, Ill) and MedCalc version 9.3.2.0 (MedCalc Software, Mariakerke, Belgium).
Results
GDF-15 Levels in Patients With Stable Angina and ACS
Baseline characteristics are shown in Table 1 . The SAP population consisted of 1352 patients (78.1% men) with a mean age of 62Ϯ10 years. GDF-15 levels in this cohort ranged from 376 to 11365 ng/L with a median (interquartile range) of 1128 (850 to 1553) ng/L; 55.8%, 26.3%, and 17.9% of the patients presented with GDF-15 levels Ͻ1200 ng/L, between 1200 and 1800 ng/L, and Ͼ1800 ng/L, respectively.
The ACS population included 877 patients (77.1% men) with a mean age of 61Ϯ10 years. GDF-15 levels ranged from 300 to 18660 ng/L, with a median (interquartile range) of 1244 (962 to 1785) ng/L; 46.6%, 29.1%, and 24.3% of these individuals presented with GDF-15 levels Ͻ1200 ng/L, between 1200 and 1800 ng/L, and Ͼ1800 ng/L, respectively. Patients with ACS had significantly higher GDF-15 levels as compared to patients with SAP (PϽ0.001).
GDF-15 in Relation to Baseline Characteristics and Clinical and Biochemical Risk Markers
By multiple regression analysis that used the natural logarithm of GDF-15 as the dependent variable, GDF-15 was independently associated with age, male gender, body mass index, drug-treated diabetes, low eGFR, and the levels of CRP and NT-proBNP, both in patients with SAP or with ACS (Table 2) . In SAP, a relation to previous or current smoking was also noted. The r 2 values of these multiple regression models were 0.48 in SAP and 0.39 in ACS. 
GDF-15 and the Risk of CHD Mortality and Nonfatal MI
In the SAP cohort, 50 CHD deaths (3.7% of the study population) and 37 nonfatal MIs (2.7%) were observed. The levels of GDF-15 were closely associated with the risk of CHD mortality (PϽ0.001; Figure 1A) . At 3.6 years (median follow-up), patients presenting with GDF-15 levels Ͻ1200 ng/L, between 1200 and 1800 ng/L, and Ͼ1800 ng/L had CHD mortality rates of 1.4%, 2.7%, and 15.0%, respectively (PϽ0.001). The levels of GDF-15 were not associated with the risk of nonfatal MI in our patients with SAP (Pϭ0.16).
In the ACS cohort, 49 CHD deaths (5.6%) and 52 nonfatal MIs (5.9%) occurred during follow-up. Increasing levels of GDF-15 were closely associated with the risk of CHD mortality (PϽ0.001; Figure 1B) . At 3.6 years, CHD mortality rates were 1.7%, 4.6%, and 14.6% in the 3 strata of GDF-15. No significant relation was observed between the levels of GDF-15 and the risk of nonfatal MI (Pϭ0.28).
GDF-15 in the Context of Other Biomarkers of Cardiovascular Risk
In the SAP cohort, a reduced eGFR and the levels of CRP, cTnI, NT-proBNP, and GDF-15 were all significantly related to the risks of CHD mortality in an age-and gender-adjusted analysis (Table 3) . To assess the independent strength of GDF-15 for CV risk prediction in comparison with established biomarkers, a backward stepwise Cox regression model was developed. In this analysis, GDF-15 (PϽ0.001), NT-proBNP (Pϭ0.011), and a cTnI level Ͼ0.01 g/L (Pϭ0.033) remained independently predictive for CHD mortality after full adjustment for age and gender, clinical variables, classical risk factors, the number of diseased vessels, and biomarker levels ( Table 3) . After further adjustment for LVEF (data available from 757 SAP patients), GDF-15 remained independently associated with the risk of CHD mortality (PϽ0.001).
Patients with ACS, CRP, NT-proBNP, and GDF-15 predicted the risk of CHD mortality after adjustment for age and gender (Table 4) . After full adjustment, only GDF-15 remained independently related to the risk of CHD mortality (PϽ0.001). After further adjustment for LVEF, GDF-15 lost its independent relation to CHD mortality (Pϭ0.18); how- High-sensitivity CRP, eGFR, NT-proBNP, and GDF-15 were not normally distributed and ln transformed; hazard ratios refer to 1 SD in the ln scale in these variables. CI indicates confidence interval; HR, hazard ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LDL, low-density lipoprotein; and HDL, high-density lipoprotein.
*Adjusted for age, gender, hypertension, diabetes (categorical), smoking (categorical), LDL/HDL-ratio, number of diseased vessels, history of myocardial infarction, and all indicated biomarkers. High-sensitivity CRP, eGFR, NT-proBNP, and GDF-15 were not normally distributed and ln transformed; HRs refer to 1 SD in the ln scale in these variables. CI indicates confidence interval; HR, hazard ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LDL, low-density lipoprotein; and HDL, high-density lipoprotein.
*Adjusted for age, gender, hypertension, diabetes (categorical), smoking (categorical), LDL/HDL-ratio, number of diseased vessels, history of myocardial infarction, and all indicated biomarkers. ever, data on LVEF were available from only 439 ACS patients, thus greatly reducing the stability of this model.
None of the tested biomarkers (eGFR, CRP, cTnI, NTproBNP, GDF-15) was associated with the risk of nonfatal MI in SAP or ACS in age-and gender-adjusted Cox regression analyses (data not shown).
Application of the 1200 and 1800 ng/L Cutoff Points for Risk Prediction
In an age-and gender-adjusted Cox regression analysis, SAP patients presenting with a GDF-15 level Ͼ1800 ng/L had a 14-fold increase in the risk of CHD mortality (PϽ0.001) as compared to patients with a GDF-15 level Ͻ1200 ng/L ( Figure  2A ). After adjustment for clinical variables and classical risk factors, the number of diseased vessels, and biomarker levels, a GDF-15 level Ͼ1800 ng/L remained associated with a 6.3-fold (Pϭ0.001) increase in the risk of CHD mortality. GDF-15 levels between 1200 and 1800 ng/L were not associated with a significant increase in the risk of CHD mortality in SAP patients after adjustment for age and gender (Figure 2A ).
In patients with ACS, a GDF-15 level Ͼ1800 ng/L was associated with a 5.5-fold (Pϭ0.001) increase in the risk of CHD mortality in the age-and gender-adjusted model, and a 4.9-fold (Pϭ0.004) increase in the risk of CHD mortality in the fully adjusted model ( Figure 2B ). GDF-15 levels between 1200 and 1800 ng/L did not predict an increase in CHD mortality in ACS patients after adjustment for age and gender ( Figure 2B ).
Incremental Prognostic Value of GDF-15 for Risk Stratification in Stable Angina and ACS
Receiver operating characteristic curve analyses were performed to explore if GDF-15 can add to the predictive value of a clinical model, which included all information that was readily available in our patients (age, gender, classical risk factors, lipid status, eGFR, and number of diseased vessels). The optimal GDF-15 levels for predicting 3.6-year CHD mortality were 1984 ng/L (sensitivity 60.9%, specificity 91.6%) in the SAP cohort and 1548 ng/L (sensitivity 77.3, specificity 72.3%) in the ACS cohort. In SAP, addition of GDF-15 improved the predictive accuracy of the clinical model concerning CHD mortality, as reflected by an increase in the c-statistic from 0.74 for the clinical model to 0.84 after addition of GDF-15 (Pϭ0.005) ( Table 5) . GDF-15 did not add significantly to the clinical model in ACS (c-statistic, 0.82 versus 0.85; Pϭ0.17; Table 5 ).
Discussion
A New Biomarker in Stable CHD
This study identifies GDF-15 as an independent predictor of CHD mortality in patients with SAP. The main findings are 1) a single measurement of GDF-15 provides independent prognostic information regarding the long-term risks of CHD mortality in patients with SAP and at least 1 documented coronary artery stenosis Ͼ30%; 2) GDF-15 cutoff levels that have been used to identify ACS patients at low (Ͻ1200 ng/L) or very high risk (Ͼ1800 ng/L) appear to be also helpful for risk stratification in SAP; 3) addition of GDF-15 significantly improves the prognostic accuracy of a clinical risk prediction model.
Several biomarkers have been shown to improve risk stratification beyond traditional risk factors in patients with stable CHD. The data are especially strong for BNP and NT-proBNP that have been linked to adverse CV outcomes in a number of studies. 18, 24, 25 Renal dysfunction, 26, 27 inflammatory biomarkers, including CRP, 28, 29 and minor cTnI elevations, 22 may also help in identifying patients at increased risk. In the present data set, all of these markers, and GDF-15, were significantly related to the risk of CHD mortality in an age-and gender-adjusted analysis. After further adjustment for clinical variables, the number of diseased vessels, biomarker levels, and even LVEF, GDF-15 remained independently predictive for CHD mortality. It should be mentioned that GDF-15 was similarly predictive for CV mortality (CHD mortality, vascular death, stroke death) and all-cause mortality in SAP (data not shown).
The associations of these biomarkers with the specific risk of (nonfatal) MI in SAP have been less well studied and appear to be somewhat less consistent. 24, 25, 28, 29 We found no significant association between the levels of GDF-15 and the risk of nonfatal MI in our SAP cohort.
GDF-15 as a Biomarker in ACS
Patients with ACS had significantly higher levels of GDF-15 as compared to patients with SAP; the difference was small, however. Moreover, no independent relation between the levels of GDF-15 and cTnI was observed in the ACS patient cohort, thus supporting the conclusion that GDF-15 does not reflect myocardial ischemia and infarction during an episode of ACS. [15] [16] [17] GDF-15 did not predict the risk of nonfatal MI in our ACS population. However, confirming and extending previous observations from ACS trial populations, [15] [16] [17] GDF-15 was a strong and independent predictor of CHD mortality in the AtheroGene ACS population. GDF-15 was similarly predictive for CV mortality and all-cause mortality (data not shown).
Pathophysiology and Predictive Value of GDF-15
We are only beginning to understand the pathobiology of GDF-15 in CV disease and the basis of its strong association with adverse CV outcomes. The predictive capacity of GDF-15 may be explained in part by the relation of GDF-15 to inflammation, which is reflected by its independent association to CRP in the present study and in ACS trial populations, 15, 16 the expression of GDF-15 in human atherosclerotic plaque macrophages, 13 and the upregulation of GDF-15 in other chronic inflammatory conditions. 30 The independent relation of GDF-15 to NT-proBNP, which has also been observed in ACS trial populations [15] [16] [17] and in patients with chronic heart failure, 31 suggests that GDF-15 may reflect, to some extent, cardiac pathologies. Supporting this hypothesis, BNP and GDF-15 are similarly induced by biomechanical stress in isolated rat cardiomyocytes and in the murine heart. 6 -8 In addition, GDF-15 appears to combine information from several CV risk factors, including age, male gender, body mass index, diabetes, and renal dysfunction. The positive correlation of GDF-15 to body mass index may be of particular interest, especially because a negative correlation to body mass index has been observed for the natriuretic peptides. 32 It is interesting to note in this regard that human adipocytes express and secrete GDF-15 on exposure to oxidative stress. 33 Together, these clinical variables and biomarkers explained Ͻ50% of the variation in the GDF-15 levels (as judged by the multiple regression r 2 values), indicating that GDF-15 carries unique additional information.
Study Limitations
First, the relatively small numbers of end points introduces a problem of low statistical power. To address this problem and avoid overadjustment, backward stepwise Cox regression analyses were performed to build the multivariable models in our study. Still, the association of some biomarkers with CHD death may not be statistically significant due to a type II error. Second, our patients were recruited in a small area in Germany, which limits the generalizability of our findings. Third, the nonrandomized design of the AtheroGene registry did not allow us to study the influence of drugs (eg, heparin) on the circulating levels of GDF-15. Before introducing GDF-15 into clinical practice, the influence of common medications on the circulating levels of this biomarker should be explored.
Clinical Implications
This study identifies GDF-15 as a promising new biomarker for risk stratification of patients with SAP and confirms GDF-15 as an independent prognostic marker in ACS.
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